25491-47-8Relevant articles and documents
COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 134-135, (2021/02/12)
The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
Dynamic Kinetic Resolution of Alkenyl Cyanohydrins Derived from α,β-Unsaturated Aldehydes: Stereoselective Synthesis of E-Tetrasubstituted Olefins
Majhi, Jadab,Turnbull, Ben W. H.,Ryu, Ho,Park, Jiyong,Baik, Mu-Hyun,Evans, P. Andrew
supporting information, p. 11770 - 11774 (2019/08/16)
A novel dynamic kinetic resolution (DKR) of tetrasubstituted alkenyl cyanohydrins prepared from the corresponding α,β-unsaturated aldehydes is described. The deprotonation of a geometrical mixture of tetrasubstituted alkenyl cyanohydrins with sodium diiso
Identification of potent, selective KDM5 inhibitors
Gehling, Victor S.,Bellon, Steven F.,Harmange, Jean-Christophe,LeBlanc, Yves,Poy, Florence,Odate, Shobu,Buker, Shane,Lan, Fei,Arora, Shilpi,Williamson, Kaylyn E.,Sandy, Peter,Cummings, Richard T.,Bailey, Christopher M.,Bergeron, Louise,Mao, Weifeng,Gustafson, Amy,Liu, Yichin,VanderPorten, Erica,Audia, James E.,Trojer, Patrick,Albrecht, Brian K.
, p. 4350 - 4354 (2016/08/18)
This communication describes the identification and optimization of a series of pan-KDM5 inhibitors derived from compound 1, a hit initially identified against KDM4C. Compound 1 was optimized to afford compound 20, a 10?nM inhibitor of KDM5A. Compound 20